Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Armand

Showing results (201-210 of 273) with videos related to

Pageof 28
Sort By:
Nature Communications|December 31, 2024
Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphomaJulia Paczkowska, Ming Tang, Kyle T Wright, et al.
Blood Advances|January 1, 2024
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLLInhye E Ahn, Danielle M Brander, Yue Ren, et al.
Blood|June 15, 2023
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphomaMwanasha H Merrill, Parastoo B Dahi, Robert A Redd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2024
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Blood Advances|December 10, 2019
Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasionKirsty Wienand, Bjoern Chapuy, Chip Stewart, et al.
The Lancet. Haematology|June 19, 2019
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trialMatthew S Davids, Danielle M Brander, Haesook T Kim, et al.
Cytotherapy|December 13, 2016
Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipientsSarah Nikiforow, Shuli Li, Karen Snow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.
Blood Advances|June 14, 2018
Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCLChelsea C Pinnix, Andrea K Ng, Bouthaina S Dabaja, et al.
Blood|May 5, 2017
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHDBradley M Haverkos, Diana Abbott, Mehdi Hamadani, et al.
Pageof 28

Showing results (201-210 of 273) with videos related to

Sort By:
Pageof 28
Nature Communications|December 31, 2024
Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphomaJulia Paczkowska, Ming Tang, Kyle T Wright, et al.
Blood Advances|January 1, 2024
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLLInhye E Ahn, Danielle M Brander, Yue Ren, et al.
Blood|June 15, 2023
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphomaMwanasha H Merrill, Parastoo B Dahi, Robert A Redd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2024
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Blood Advances|December 10, 2019
Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasionKirsty Wienand, Bjoern Chapuy, Chip Stewart, et al.
The Lancet. Haematology|June 19, 2019
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trialMatthew S Davids, Danielle M Brander, Haesook T Kim, et al.
Cytotherapy|December 13, 2016
Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipientsSarah Nikiforow, Shuli Li, Karen Snow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.
Blood Advances|June 14, 2018
Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCLChelsea C Pinnix, Andrea K Ng, Bouthaina S Dabaja, et al.
Blood|May 5, 2017
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHDBradley M Haverkos, Diana Abbott, Mehdi Hamadani, et al.
Pageof 28